ライフサイエンスコーパス: preventive therapy

1 group (antiretroviral therapy and isoniazid preventive therapy).

2 works, including prophylactic, emergency, or preventive therapy.

3 Infected patients were offered preventive therapy.

4 rrences may occur in 30% of patients without preventive therapy.

5 ed, phased-implementation trial of isoniazid preventive therapy.

6 biomarkers that indicate early responses to preventive therapy.

7 of follow-up for those initiating isoniazid preventive therapy.

8 improve targeted, cost-effective delivery of preventive therapy.

9 undergo limited evaluations, and few receive preventive therapy.

10 ) among contacts with LTBI who did not start preventive therapy.

11 not, they were offered 9 months of isoniazid preventive therapy.

12 ent TB but with LTBI diagnosis, 45% received preventive therapy.

13 limited impact may be expected of expanding preventive therapy.

14 d by the US Food and Drug Administration for preventive therapy.

15 nd infection, yet few were receiving routine preventive therapy.

16 tion of antiretroviral therapy and isoniazid preventive therapy.

17 ion and strengthening the case for secondary preventive therapy.

18 tial to provide a new dimension to secondary preventive therapy.

19 ibitors varespladib methyl and darapladib as preventive therapy.

20 nd in reference subjects who had received no preventive therapy.

21 communicating risks and supporting intensive preventive therapy.

22 y benefit from early spectacle correction or preventive therapy.

23 may aid in determining prognosis and guiding preventive therapy.

24 tuberculosis transmission and on the use of preventive therapy.

25 irculatory changes as an approach to earlier preventive therapy.

26 reater confidence in the safety of isoniazid preventive therapy.

27 niazid preventive therapy, and 82% completed preventive therapy.

28 ied granulomas) were offered isoniazid (INH) preventive therapy.

29 rpose in assessing indications for isoniazid preventive therapy.

30 n populations will require widespread use of preventive therapy.

31 hat could potentially have been avoided with preventive therapy.

32 Only 21 (2%) HHCs were on preventive therapy.

33 a randomized, controlled trial of isoniazid preventive therapy.

34 TB patients, including higher completion of preventive therapy.

35 finding and increase uptake of tuberculosis preventive therapy.

36 of intensified case finding and tuberculosis preventive therapy.

37 men were attributing age-related symptoms to preventive therapy.

38 evated risk of breast cancer and considering preventive therapy.

39 ients who are at risk of relapse in time for preventive therapy.

40 offered antiretroviral therapy and isoniazid preventive therapy.

41 ening for symptoms, active case finding, and preventive therapy.

42 f HPVs is critical for developing additional preventive therapies.

43 ht provide a better tool for selecting these preventive therapies.

44 ronary calcium scores, for more personalized preventive therapies.

45 potential risk factors and to develop novel preventive therapies.

46 presymptomatic phase, and thus implementing preventive therapies.

47 te may represent novel targets for acute and preventive therapies.

48 managed in terms of risk stratification and preventive therapies.

49 archers hope to better define treatments and preventive therapies.

50 ections may lead to important therapeutic or preventive therapies.

51 risk is important for cost-effective use of preventive therapies.

52 minimize the healthy user bias in studies of preventive therapies.

53 is group is paramount to optimize the use of preventive therapies.

54 e for risk counseling and the development of preventive therapies.

55 atment trials, and increasing application of preventive therapies.

56 ians and researchers insights into potential preventive therapies.

57 ogression and could provide a target for new preventive therapies.

58 h risk for breast cancer who should consider preventive therapies.

59 veloping TB despite initiation of ART and TB preventive therapies.

60 evastating form of human epilepsy that lacks preventive therapies.

61 ocedures and the safety and effectiveness of preventive therapies.

62 future cardiovascular events despite current preventive therapies.

63 More preventive therapies (283 vs. 74; HR: 4.03 [95% CI: 3.12

64 9 (50%) fit current guidelines for isoniazid preventive therapy, 84 (20%) we intended to treat comple

65 5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute risk diffe

66 For preventive therapy, a number of medications have been st

67 ttributed to treatments, including secondary preventive therapies after myocardial infarction or reva

68 andates adequate attention to cardiovascular preventive therapy after diagnosis of breast cancer.

69 The effectiveness of preventive therapy against incident tuberculosis was est

70 uring influenza season would be an effective preventive therapy against influenza in this high-risk p

71 rtemisinin-piperaquine (DP) and intermittent preventive therapy against malaria in pregnancy (IPT) wi

72 nfection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtainin

73 proaches also show promise as both acute and preventive therapies, although further studies are neede

74 ed to modern populations with greater use of preventive therapy, although the magnitude of overestima

75 prioritize active case finding or isoniazid preventive therapy among children exposed to TB.

76 ardial infarction (MI) improves adherence to preventive therapies and reduces clinical events.

77 of US adults with PAD who are not receiving preventive therapies and whether treatment is associated

78 black women less often received appropriate preventive therapy and adequate risk factor control desp

79 is); and (2) estimating the effectiveness of preventive therapy and BCG vaccination on the risk of de

80 We review the evidence for TB preventive therapy and discuss the future of TB preventi

81 and weekly dosing is under investigation for preventive therapy and for the continuation phase of tre

82 r we outline challenges to implementation of preventive therapy and provide pragmatic suggestions for

83 individuals who were eligible for isoniazid preventive therapy and the poor adherence with a complet

84 d a medical examination, 91% began isoniazid preventive therapy, and 82% completed preventive therapy

85 terventions, such as vaccination programs or preventive therapy, and could also allow for study of ba

86 Screening, preventive therapy, and surveillance for tuberculosis ar

87 n unsatisfactory because available acute and preventive therapies are either ineffective or poorly to

88 vior, and willingness to submit to long-term preventive therapies are significantly influenced by cul

89 utcomes associated with the long-term use of preventive therapies are subject to the so-called "healt

90 Unfortunately, both preventive therapies are underused in low-income and hig

91 Trials of novel, preventive therapies are urgently needed to inform treat

92 Specific recommendations for preventive therapy are being made, but prospective clini

93 he adverse effects and acceptability of this preventive therapy are largely uncharacterized.

94 Isoniazid preventive therapy as an adjunct to ART prevents tubercu

95 Children were started on preventive therapy as per local guidance: ofloxacin, eth

96 We further advocate for tuberculosis preventive therapy as the core of a renewed worldwide fo

97 erculosis infection, medical evaluation, and preventive therapy, as well as the number of active tube

98 s of age, 2,106 contacts (50%) initiated INH preventive therapy at enrollment.

99 is inappropriate and suggested that the term preventive therapy better represents this feature of man

100 fter surgery remains the mainstay of current preventive therapy, but the potential for other antiplat

101 suggests the use of statins as tuberculosis preventive therapy by inhibiting PDIM spread.

102 ting, post-treatment follow-up and secondary preventive therapy can accelerate declines in tuberculos

103 ly that antiretroviral therapy and isoniazid preventive therapy can be started safely in people whose

104 f the 76 household contacts who received INH preventive therapy compared with 3% (8 of 273) of those

105 educing treatment delay, providing isoniazid preventive therapy continuously to human immunodeficienc

106 Cotrimoxazole preventive therapy (CPT) in human immunodeficiency virus

107 The role of co-trimoxazole preventive therapy (CPT) in reducing leading causes of i

108 Cotrimoxazole preventive therapy (CPT) is recommended for all human im

109 trial data, we estimate the degree to which preventive therapies cure latent Mycobacterium tuberculo

110 tuberculosis infection and directly observed preventive therapy (DOPT) in methadone maintenance clini

111 y means of community-based directly observed preventive therapy (DOPT).

112 ety of IPT and new short-course tuberculosis preventive therapies during pregnancy.

113 th the safety of IPT and new short-course TB preventive therapies during pregnancy.

114 isks associated with initiation of isoniazid preventive therapy during pregnancy appeared to be great

115 to provide at least 3 doses of intermittent preventive therapy during pregnancy at each scheduled an

116 and quasi-randomized trials of intermittent preventive therapy during pregnancy with sulfadoxine-pyr

117 redict disease risk, and potentially predict preventive therapy efficacy.

118 totoxic effects will be desirable to develop preventive therapies for BRONJ.

119 earlier age and the known benefits of using preventive therapies for PAD, this is the perfect time t

120 omen with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during

121 e with TBI were offered isoniazid-rifampicin preventive therapy for 3 months.

122 Twice-weekly isoniazid preventive therapy for 6 months or rifampicin and pyrazi

123 active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among S

124 following two preventive therapy strategies: preventive therapy for all household contacts, or preven

125 enous immunoglobulin (IVIG) was evaluated as preventive therapy for CHB.

126 early diagnosis emphasise the importance of preventive therapy for child contacts of patients with t

127 finding and a high uptake and completion of preventive therapy for children were achieved.

128 nts and hard-to-reach groups, and the use of preventive therapy for contacts of cases of infectious m

129 Preventive therapy for HIV-1-seropositive, PPD-positive

130 Standard preventive therapy for inactive pulmonary tuberculosis (

131 nario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral the

132 Isoniazid preventive therapy for latent tuberculosis (TB) infectio

133 atients with tuberculosis, and screening and preventive therapy for latent tuberculosis infections in

134 duced PVOD in rats and should be tested as a preventive therapy for MMC-induced PVOD in humans.

135 ese findings suggest that expanded access to preventive therapy for older children and young-adult ho

136 ntive therapy for all household contacts, or preventive therapy for only household contacts with a po

137 96 we evaluated a 4-mo, four-drug regimen of preventive therapy for patients with inactive TB, mostly

138 episodes of injury and may be beneficial as preventive therapy for patients with or at risk of devel

139 4-mo regimen had no advantage over standard preventive therapy for persons with inactive pulmonary T

140 th Crotalus atrox venom (Cv-PC) as potential preventive therapy for reducing perioperative hemorrhage

141 George Comstock's work on preventive therapy for TB demonstrated the use of epidem

142 omprehensive control strategies that combine preventive therapy for the most high-risk populations an

143 eatment follow-up examinations and secondary preventive therapy for tuberculosis in a tuberculosis-en

144 Preventive therapy for tuberculosis reduces the risk of

145 es of tuberculosis; 37 were in the isoniazid preventive therapy group (2.3 per 100 person-years, 95%

146 rical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral therapy and iso

147 ns in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 individuals

148 p and 46 (11%) participants in the isoniazid preventive therapy group.

149 uberculosis therapy and 426 to the isoniazid preventive therapy group.

150 p and 97 (23%) participants in the isoniazid preventive therapy group.

151 lusions: Household contacts who received INH preventive therapy had a lower incidence of tuberculosis

152 No safe and effective preventive therapy has been identified, but promising ne

153 P panel can refine risk in women who receive preventive therapy has not been directly assessed previo

154 Preventive therapies have been demonstrated to improve o

155 This has become of paramount importance, as preventive therapies have evolved for recurrent attacks

156 ed trials testing the safety and efficacy of preventive therapies in infants with CF are lacking.

157 chemotaxis can unravel potential targets for preventive therapies in inflammatory disease conditions.

158 emature death may assist in the targeting of preventive therapies in order to improve overall health.

159 ortality risk are needed to optimally target preventive therapies in patients with coronary artery di

160 ide (CGRP) pathway is a promising target for preventive therapies in patients with migraine.

161 dies will aid in design and effective use of preventive therapies in the very low birth weight infant

162 ptomatic participants were offered isoniazid preventive therapy in both arms.

163 d induction therapy may lead to personalized preventive therapy in further studies.

164 duce early mortality compared with isoniazid preventive therapy in high-burden settings.

165 d preventive therapy (IPT) is recommended as preventive therapy in HIV-infected persons.

166 MTB) infection and indications for isoniazid preventive therapy in HIV-infected persons.

167 mpirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiatin

168 and meta-analysis showed that using MMF as a preventive therapy in NMOSD patients can significantly r

169 ortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with advanced HI

170 tematic tuberculosis screening and isoniazid preventive therapy in outpatients with advanced HIV dise

171 Antimalarial intermittent preventive therapy in pregnancy (IPTp) and insecticide-t

172 e-pyrimethamine (SP) is used as intermittent preventive therapy in pregnancy (IPTp) for malaria in su

173 monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucia

174 WHO recommends intermittent preventive therapy in pregnancy with sulfadoxine-pyrimet

175 Yet, SP is efficacious as intermittent preventive therapy in pregnant women (IPTp) and infants

176 ns for approaches to empirical treatment and preventive therapy in some regions of the world.

177 ses have called for the use of probiotics as preventive therapy in subsets of this population.

178 -reported symptoms on long-term adherence to preventive therapy in the United Kingdom sample of the I

179 uideline changes affected identification for preventive therapy in young adults with premature myocar

180 urrent are promising candidates for an early preventive therapy in young phenotype-negative subjects

181 A total of 118 persons received preventive therapy, including 56 young children who were

182 rate of hepatotoxicity in persons receiving preventive therapy increased with increasing age (chi2 f

183 omes by increasing the use of evidence-based preventive therapies informed by plaque burden.

184 Preventive therapies initiated after myocardial infarcti

185 From the median time for preventive therapy initiation (50 days), fatal and nonfa

186 e I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination with bacil

187 rld Health Organization recommends isoniazid preventive therapy (IPT) for HIV-positive contacts and t

188 Isoniazid preventive therapy (IPT) for HIV-TB coinfected individua

189 Trials of isoniazid preventive therapy (IPT) for people living with HIV in s

190 Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-in

191 d contacts (<5 years) who received isoniazid preventive therapy (IPT) had developed disease compared

192 erculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected with human

193 duced a high rate of completion of isoniazid preventive therapy (IPT) in those persons after their di

194 Isoniazid preventive therapy (IPT) is recommended as preventive th

195 Isoniazid preventive therapy (IPT) is widely used to protect again

196 We also hypothesized that isoniazid preventive therapy (IPT) may revert LTBI diagnoses becau

197 Isoniazid preventive therapy (IPT) reduces mortality among HIV-inf

198 Isoniazid preventive therapy (IPT) reduces mortality among individ

199 Isoniazid preventive therapy (IPT) was prescribed to <1% of ART en

200 ulin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing TST-negat

201 llow-up examinations and secondary isoniazid preventive therapy (IPT), alone and in combination, amon

202 iretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-infected adu

203 antiretroviral therapy (ART), and isoniazid preventive therapy (IPT).

204 as insecticide-treated nets and intermittent preventive therapy (IPT).

205 ive either empiric TB treatment or isoniazid preventive therapy (IPT).

206 ive either empiric TB treatment or isoniazid preventive therapy (IPT).

207 sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pr

208 Tuberculosis preventive therapy is a poorly used method that is essen

209 Preventive therapy is an important element of syphilis c

210 h by rupture for larger AAAs, no guidance or preventive therapy is currently available for the >90% o

211 Preventive therapy is effective, but current regimens ar

212 TB preventive therapy is highly efficacious in the preventi

213 n against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficien

214 These data indicate that INH preventive therapy is not routinely indicated in anergic

215 Preventive therapy is probably indicated in about a thir

216 Isoniazid preventive therapy is recommended in HIV-positive adults

217 Patients who adhere to preventive therapies may be more likely to engage in a b

218 scuss how risk factor modification and other preventive therapies may help curb the rising incidence

219 he willingness of MDR-TB HHCs to take MDR-TB preventive therapy (MDR TPT) to decrease their risk of T

220 r younger, only half this group received INH preventive therapy.Measurements and Main Results: Among

221 were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667) between Ja

222 Preventive therapy of sickle pain is best achieved with

223 n.Objectives: To evaluate the effects of INH preventive therapy on the contacts of patients with mult

224 We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people

225 d (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months (could be

226 pregnant women living with HIV for isoniazid preventive therapy or for further investigation for tube

227 s could be due to the lack of cure following preventive therapy or reinfection with rapid progression

228 py naive individuals following completion of preventive therapy (or placebo) was fitted to posttherap

229 26% vs. 43%), statin (16% vs. 26%), or other preventive therapies (p < 0.001 for all).

230 to better identify individuals to target for preventive therapy, predict disease risk, and potentiall

231 ce sustainable large scale implementation of preventive therapy programmes.

232 ity-based tuberculin screening and isoniazid preventive therapy project among high-risk inner-city re

233 his community-based tuberculin screening and preventive therapy project were the low proportion of in

234 Effective preventive therapy (PT) exists, but current tests have l

235 Preventive therapy (PT) was prescribed for 324 (34%) and

236 the tolerability and toxicity of a standard preventive therapy regimen given to children exposed to

237 This 3-drug preventive therapy regimen was well tolerated and few ch

238 community-based programs to be efficacious, preventive therapy regimens that are of shorter duration

239 istory to model outcomes, assuming different preventive therapy regimens, ages, and TST positivity pr

240 e evaluated the safety and efficacy of three preventive-therapy regimens in a setting where exposure

241 effectiveness of contact investigations and preventive therapy remains poorly understood.

242 FQN preventive therapy resulted in health system savings, lo

243 In our model, FQN preventive therapy resulted in substantial health system

244 We assumed that without preventive therapy, seven cases of tuberculosis would ha

245 latent Mycobacterium tuberculosis infection (preventive therapy), shorten the time between disease on

246 ying increased surveillance or even low-risk preventive therapies should these be available), identif

247 eruvian national guidelines specify that INH preventive therapy should be provided to contacts aged 1

248 e algorithm that predicts benefit, isoniazid preventive therapy should be recommended to all patients

249 Isoniazid preventive therapy significantly reduced tuberculosis ri

250 Co-trimoxazole preventive therapy started before or with ART, irrespect

251 adverse events, comparing the following two preventive therapy strategies: preventive therapy for al

252 ease in one patient, suggesting that primary preventive therapy studies on disease modification are n

253 anergic subjects in the placebo arms of the preventive therapy study underwent repeat skin testing a

254 ial to benefit from more intensive secondary preventive therapy such as treatment with vorapaxar.

255 Antimalarial intermittent preventive therapy (sulfadoxine-pyrimethamine) and insec

256 to protect the association cortex, including preventive therapies that are challenging to test in hum

257 heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk

258 e of invasive angiography and alterations in preventive therapies that were associated with a halving

259 ally despite the availability of life-saving preventive therapy, the implantable cardioverter defibri

260 on are needed, such as earlier initiation of preventive therapy through rapid diagnosis of adult case

261 screening ankle-brachial index benefit from preventive therapies to reduce cardiovascular risk is un

262 A paradigm shift from preventive therapy to aggressive plaque regression and e

263 Based on the available data, giving preventive therapy to all household contacts would proba

264 herent, are not sufficient to recommend mass preventive therapy to healthy women.

265 The provision of preventive therapy to vulnerable children following expo

266 the potential, especially with provision of preventive therapy, to augment a comprehensive package o

267 Tuberculosis preventive therapy (TPT) is highly effective at preventi

268 rgent need for improved detection, vaccines, preventive therapy, treatment, and support for affected

269 ected subjects screened for the tuberculosis preventive therapy trial compared with 10% of 682 HIV-no

270 HIV-infected persons being screened for a TB preventive therapy trial in Uganda with an initial purif

271 lts followed prospectively in a tuberculosis preventive therapy trial in Uganda.

272 had completed at least 5 months of isoniazid preventive therapy, unless they had completed treatment

273 luding 56 young children who were prescribed preventive therapy until skin tests performed at least 1

274 gh burden of tuberculosis that are expanding preventive therapy use must decide how tuberculosis infe

275 Preventive therapy using imatinib or nilotinib inhibited

276 hout cardiovascular disease, use of multiple preventive therapies was associated with 65% lower all-c

277 , TST-positive patients who did not take INH preventive therapy was 5.0 per 100 person-yr, compared w

278 The effectiveness of preventive therapy was 63% (adjusted HR 0.37 [95% CI 0.3

279 d hepatotoxicity during clinically monitored preventive therapy was lower than has been reported prev

280 berculosis in the three groups that received preventive therapy was lower than the rate in the placeb

281 Preventive therapy was provided to 799 of 888 (90%) scho

282 ted no evidence that the effect of isoniazid preventive therapy was restricted to patients who were p

283 terized reminders on the rates at which four preventive therapies were ordered for inpatients.

284 Gender disparities in recommendations for preventive therapy were explained largely by the lower p

285 below 200/microl and who were not receiving preventive therapy were nine times more likely to develo

286 depending on the severity of the headache), preventive therapy (when the headaches are frequent or c

287 cs will probably best serve as adjunctive or preventive therapies, which suggests that conventional a

288 An opportunity exists for preventive therapy, which should improve the reproductiv

289 Short-course preventive therapy with 12 doses of once-weekly rifapent

290 Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimetha

291 nt women in sub-Saharan Africa, intermittent preventive therapy with 3 or more doses of sulfadoxine-p

292 Children not receiving preventive therapy with a positive result for tuberculos

293 Providing preventive therapy with contact tracing nearly doubled t

294 Preventive therapy with lamivudine for patients who test

295 Preventive therapy with LDE223 almost completely impeded

296 Where the risk of reinfection is lower, preventive therapy with more curative drugs should be pr

297 xacin as optimal therapy for pouchitis, when preventive therapy with probiotics is not successful.

298 All 157 students were prescribed preventive therapy with rifampin (10 mg/kg up to 600 mg

299 In conclusion, preventive therapy with rifampin was well tolerated and

300 require more frequent doses of intermittent preventive therapy with SP than do HIV-uninfected (HIV(-

301 Intermittent preventive therapy with sulfadoxine-pyrimethamine to con